Pooled safety analysis of 48 phase II/III/IV trials on secukinumab for tx of PsO, PsA and axSpA Well tolerated No new long term safety signals IBD, malginancy, MACE remain low @RheumNow #ACR23 Abs#1436 https://t.co/6dzdO5Vpuc